GeneHealth - Your precision medicine

Retinitis Pigmentosa 26

Disease Details

Family Health Simplified

Buy Membership

Description: Retinitis pigmentosa 26 is a type of inherited degenerative eye disease that results in progressive vision loss due to the breakdown and loss of cells in the retina.

One-sentence description of the disease: Retinitis pigmentosa 26 is a genetic disorder causing progressive degeneration of the retina, leading to vision impairment and eventual blindness.
Type: Retinitis pigmentosa 26 (RP26) is a type of inherited retinal dystrophy. The genetic transmission of RP26 follows an autosomal recessive pattern.
Signs And Symptoms: Retinitis Pigmentosa 26 (RP26) is a subset of the broader group of retinitis pigmentosa disorders, characterized by the progressive degeneration of the retina. Signs and symptoms generally include:

- Night blindness (nyctalopia): Difficulty seeing in low-light conditions is often one of the earliest symptoms.
- Tunnel vision: Loss of peripheral vision, leading to a constricted field of view.
- Photopsia: Seeing flashes of light.
- Difficulty with color perception, particularly in the later stages.
- Progressive loss of central vision, which eventually can lead to complete blindness.

The progression and severity of symptoms can vary widely among individuals.
Prognosis: Retinitis pigmentosa 26 (RP26) is a type of inherited retinal degeneration. The prognosis varies widely among individuals but generally involves a gradual decline in vision over time. Night blindness often occurs first, followed by loss of peripheral vision and, eventually, central vision, which may lead to legal blindness. While there is currently no cure, various supportive treatments and adaptive strategies can help manage symptoms and improve quality of life.
Onset: Retinitis Pigmentosa 26 (RP26) typically has an onset in childhood or adolescence.
Prevalence: Retinitis pigmentosa 26 (RP26) does not have a specified prevalence rate that is well-documented in scientific literature. Generally, retinitis pigmentosa as a whole affects approximately 1 in 4,000 people worldwide, but specific data for RP26 is not available.
Epidemiology: Retinitis pigmentosa 26 (RP26) is a type of retinitis pigmentosa, a group of inherited eye diseases that cause progressive vision loss due to the degeneration of the retina. The prevalence of retinitis pigmentosa, in general, is estimated to be about 1 in 4,000 individuals worldwide, although specific prevalence data for RP26 may vary and is not well-documented.
Intractability: Retinitis pigmentosa 26 (RP26) is a genetic disorder that leads to progressive vision loss due to the degeneration of photoreceptor cells in the retina. It is generally considered intractable, as there is currently no cure for the disease. However, various treatments and interventions, such as vitamin A supplementation, use of low-vision aids, and participation in clinical trials for gene therapy and retinal implants, may help manage symptoms and slow disease progression.
Disease Severity: Retinitis pigmentosa 26 (RP26) is a subtype of retinitis pigmentosa, characterized by progressive vision loss due to the degeneration of photoreceptor cells in the retina. The severity can vary significantly among individuals. It generally starts with night blindness, followed by peripheral vision loss, and eventually can result in central vision deterioration. Disease progression is typically gradual but can lead to significant visual impairment over time.
Healthcare Professionals: Disease Ontology ID - DOID:0110368
Pathophysiology: Retinitis Pigmentosa 26 (RP26) is a subtype of retinitis pigmentosa, which is a group of genetic disorders that cause progressive retinal degeneration. In RP26, mutations typically occur in the CERKL gene, which is thought to be involved in protecting retinal cells from oxidative stress.

Pathophysiology: The mutations in the CERKL gene lead to a loss of function of the encoded ceramide kinase-like protein. This compromises the survival of photoreceptor cells, particularly rods, due to increased susceptibility to oxidative damage. Over time, the rod cells deteriorate, followed by cone cells, leading to the characteristic progressive loss of vision observed in retinitis pigmentosa.
Carrier Status: Retinitis pigmentosa 26 (RP26) is a genetic disorder that primarily affects the eyes, leading to progressive vision loss. Being an autosomal recessive condition, having carrier status means that an individual carries one copy of the mutated gene without showing symptoms of the disease. Carriers can potentially pass the gene to their offspring. If both parents are carriers, there is a 25% chance with each pregnancy that the child will inherit both copies of the mutated gene and thus be affected by RP26.
Mechanism: Retinitis pigmentosa 26 (RP26) is a type of retinitis pigmentosa, a group of genetic disorders that lead to progressive retinal degeneration and vision loss. RP26 is specifically associated with mutations in the gene EYS (eyes shut homolog), which is vital for proper photoreceptor function.

**Mechanism and Molecular Mechanisms:**
1. **Gene Involved**: EYS gene mutations are primarily implicated in RP26.
2. **Protein Function**: The EYS protein is crucial for the structural integrity and function of photoreceptor cells in the retina.
3. **Pathogenesis**: Mutations in the EYS gene lead to dysfunctional or absent EYS protein, causing photoreceptor cells (rods and cones) to degenerate. Rod cells, responsible for peripheral and night vision, are typically affected first. As the disease progresses, cone cells, required for color and central vision, also degenerate.
4. **Cellular Impact**: The loss of photoreceptors leads to the accumulation of pigmented material in the retina and progressive vision loss.
5. **Inheritance Pattern**: RP26 primarily follows an autosomal recessive inheritance pattern, meaning that an individual must inherit two defective copies of the EYS gene, one from each parent, to manifest the disease.

Understanding these molecular mechanisms is critical for the development of targeted therapies and genetic interventions aimed at treating or slowing the progression of RP26.
Treatment: Retinitis pigmentosa 26 (RP26) is a subtype of retinitis pigmentosa, a group of genetic disorders that cause progressive peripheral vision loss and night vision difficulties, which can eventually lead to central vision loss. There is no cure for RP26, but treatments primarily focus on managing symptoms and preserving vision for as long as possible. Current treatment strategies may include:

1. **Vitamin A Palmitate**: High-dose vitamin A supplements have been shown to slow the progression of some forms of retinitis pigmentosa.
2. **Omega-3 Fatty Acids**: These may also have a protective effect on retinal cells.
3. **Gene Therapy**: Research is ongoing into gene therapy approaches that might correct the genetic defects causing RP26.
4. **Retinal Implants**: These are being developed to restore partial vision in individuals with severe vision loss.
5. **Vision Aids**: Tools and technologies, such as magnifiers and specialized glasses, can help individuals make the most of their remaining vision.
6. **Regular Monitoring**: Eye examinations and consultations with a specialist can help manage the condition and monitor its progression.

Experimental treatments and research are ongoing, aiming to find more effective therapies for individuals with RP26.
Compassionate Use Treatment: For retinitis pigmentosa 26 (RP26), compassionate use, off-label, or experimental treatments may sometimes be considered when standard therapies are not effective, or when patients are not eligible for clinical trials. Some potential approaches might include:

1. **Gene Therapy:** Experimental gene therapy aims to deliver a functional copy of the defective gene to the retina to restore its function. Clinical trials are ongoing for various forms of retinitis pigmentosa.

2. **Retinal Implants:** Devices like the Argus II retinal prosthesis system have been approved for specific types of retinitis pigmentosa and are being researched for RP26. These implants aim to provide a form of artificial vision.

3. **Pharmacological Treatments:** Certain drugs, such as valproic acid, have been studied off-label for RP. However, the effectiveness of such treatments varies, and they are not yet widely accepted.

4. **Stem Cell Therapy:** Experimental stem cell treatments aim to replace or repair damaged retinal cells, though this approach is still under investigation and not widely available outside clinical trials.

5. **Nutritional Supplements:** High doses of vitamin A palmitate and omega-3 fatty acids have been studied for their potential to slow the progression of retinitis pigmentosa, though they are not a cure and are used with caution due to potential side effects.

6. **Optogenetics:** This is an emerging experimental approach that involves making remaining retinal cells sensitive to light, potentially restoring some vision.

Patients interested in these treatments should consult their ophthalmologist or retinal specialist to discuss the potential risks and benefits and to consider enrollment in appropriate clinical trials.
Lifestyle Recommendations: For individuals with retinitis pigmentosa 26, here are some lifestyle recommendations that may help manage the condition:

1. **Regular Eye Exams:** Regular check-ups with an ophthalmologist to monitor the progression of the disease and make necessary adjustments in treatment.

2. **Ultraviolet (UV) Protection:** Wearing sunglasses that block UV rays to protect the eyes and prevent further retinal damage.

3. **Healthy Diet:** Consuming a balanced diet rich in antioxidants and omega-3 fatty acids, which may support overall eye health. Foods like leafy greens, fish, nuts, and seeds are beneficial.

4. **Low Vision Aids:** Utilizing low vision aids and adaptive technologies, such as magnifying glasses, specialized software, and other tools that can help with daily activities.

5. **Safe Environment:** Making home and workspaces safer by improving lighting and reducing tripping hazards to accommodate declining peripheral vision.

6. **Support Networks:** Engaging with support groups and counseling services can provide emotional support and practical advice from others experiencing similar challenges.

7. **Exercise:** Regular physical activity to maintain overall health, which can contribute positively to mental and physical well-being.

8. **Smoking Cessation:** Avoiding smoking, as it can have detrimental effects on overall eye health.

These recommendations should be tailored to individual needs and discussed with healthcare providers for optimal management.
Medication: Retinitis pigmentosa 26 (RP26) does not have a specific medication treatment that can cure or halt its progression. However, some general approaches for retinitis pigmentosa include:

1. Vitamin A supplementation: High doses of Vitamin A palmitate may slow the progression in some patients but should be taken under medical supervision due to potential toxicity.
2. Omega-3 fatty acids: Specifically, docosahexaenoic acid (DHA) may provide some benefit.
3. Antioxidants and other nutritional supplements: These are being studied for their potential protective effects on retinal cells.

Always consult with a healthcare professional for personalized treatment options and management strategies.
Repurposable Drugs: There are currently no widely recognized or approved repurposable drugs specifically for Retinitis Pigmentosa 26. Clinical trials and research are ongoing to explore potential treatments that could be repurposed, but no definitive options have been established. Experimental treatments, gene therapy, and supportive management are some of the approaches being investigated. Consultation with a specialist for the most up-to-date information is recommended.
Metabolites: Retinitis pigmentosa 26 (RP26) is a form of Retinitis Pigmentosa, a group of genetic disorders that cause retinal degeneration. Specific information about metabolites directly associated with RP26 is not widely detailed in current scientific literature. Metabolomic profiling studies of Retinitis Pigmentosa in general may identify changes in various metabolites, such as alterations in lipid metabolism or oxidative stress markers, but these are not specific to RP26.

"nan" could refer to "nanotechnology" in the context of RP26, where emerging nanotechnological approaches are being investigated for potential treatments, such as targeted drug delivery systems or retinal implants to slow disease progression or restore vision.

Further detailed research studies would be necessary to provide specific metabolite profiles and advanced nanotechnological interventions for RP26.
Nutraceuticals: For retinitis pigmentosa 26 (RP26), there are no specific nutraceuticals conclusively proven to treat or halt the progression of the disease. While some studies suggest that certain vitamins and antioxidants (e.g., Vitamin A, Omega-3 fatty acids) may offer potential benefits in slowing retinal degeneration, their effectiveness is not universally established and they should be discussed with a healthcare provider. Nanotechnology-based treatments are still under research and not widely available for clinical use at this time.
Peptides: For retinitis pigmentosa 26 (RP26), research into peptides and nanoparticles (nano) as therapeutic strategies is ongoing. Peptides are being investigated to potentially inhibit the progression of retinal degeneration by promoting cell survival or reducing apoptosis. Nanoparticles are being explored as delivery systems to enhance the targeted delivery of drugs or genes to retinal cells, improving therapeutic efficacy and minimizing side effects.